ロード中...
Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma
The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma. CD30 is rarely expressed by normal cells, and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates (...
保存先:
| 出版年: | Cancer J |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5042201/ https://ncbi.nlm.nih.gov/pubmed/26841013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000168 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|